文献速递肿瘤 PET/CT

18F-FES与18F-FDG PET/CT在转移性浸润性小叶乳腺癌中的头对头评估

Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer.
PubMed 文献 · J Nucl Med · 2020-07-17

该研究回顾了纪念斯隆凯特琳癌症中心2008至2019年间6项前瞻性临床试验,纳入92例转移性乳腺癌患者,其中14例(15%)为浸润性小叶癌。7例小叶癌患者在研究性18F-FES PET/CT前后5周内接受了18F-FDG PET/CT且治疗无改变,分析显示7例中5例(71%)18F-FES PET/CT检出的转移灶多于18F-FDG PET/CT,且这5例中18F-FES阳性病灶的SUVmax更高。作者认为18F-FES PET/CT在转移性小叶癌检测方面优于18F-FDG PET/CT,并建议考虑开展更大规模的前瞻性试验。

要点

  • 7例可比较的浸润性小叶癌患者中,5例(71%)18F-FES PET/CT检出的转移灶数量多于18F-FDG PET/CT。
  • 同5例患者中,18F-FES阳性病灶的SUVmax高于18F-FDG阳性病灶的SUVmax。
  • 1例患者有18F-FES阳性转移灶但无对应18F-FDG阳性转移灶;无患者仅有18F-FDG阳性远处转移而无18F-FES阳性远处转移。

核心结论

  • 在转移性浸润性小叶癌患者中,18F-FES PET/CT在检测转移灶方面较18F-FDG PET/CT表现更优。
  • 作者认为应考虑开展更大规模的前瞻性18F-FES PET/CT试验,以评估雌激素受体靶向影像在该组织学类型乳腺癌患者中的临床价值。

研究设计与样本

  • 研究回顾了纪念斯隆凯特琳癌症中心2008年至2019年间开展的6项使用18F-FES PET/CT的前瞻性临床试验。
  • 这些试验共纳入92例转移性乳腺癌患者,其中14例(15%)为浸润性小叶癌组织学。
  • 14例浸润性小叶癌患者中7例在研究性18F-FES PET/CT前后5周内接受了18F-FDG PET/CT且期间治疗无改变,对这7对扫描进行分析。

主要发现

  • 7对可比较的扫描中,共发现254个18F-FES阳性病灶(SUVmax范围2.6-17.9)和111个18F-FDG阳性可疑恶性病灶(SUVmax范围3.3-9.9)。
  • 7例浸润性小叶癌患者中5例(71%)的18F-FES PET/CT检出的转移灶数量多于18F-FDG PET/CT。
  • 同5例患者中,18F-FES阳性病灶的SUVmax高于18F-FDG阳性病灶的SUVmax。
  • 1例患者有18F-FES阳性转移灶但无对应的18F-FDG阳性转移灶。
  • 无患者出现18F-FDG阳性远处转移而无18F-FES阳性远处转移,但1例患者的肝转移在18F-FDG上可见而在18F-FES PET上未见。

局限性

  • 作者建议应考虑开展更大规模的前瞻性18F-FES PET/CT试验,以评估雌激素受体靶向影像在该组织学类型乳腺癌患者中的临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Invasive lobular carcinoma (ILC) demonstrates lower conspicuity on 18F-FDG PET than the more common invasive ductal carcinoma. Other molecular imaging methods may be needed for evaluation of this malignancy. As ILC is nearly always (95%) estrogen receptor (ER)-positive, ER-targeting PET tracers such as 16α-18F-fluoroestradiol (18F-FES) may have value. We reviewed prospective trials at Memorial Sloan Kettering Cancer Center using 18F-FES PET/CT to evaluate metastatic ILC patients with synchronous 18F-FDG and 18F-FES PET/CT imaging, which allowed a head-to-head comparison of these 2 PET tracers. Methods: Six prospective clinical trials using 18F-FES PET/CT in patients with metastatic breast cancer were performed at Memorial Sloan Kettering Cancer Center from 2008 to 2019. These trials included 92 patients, of whom 14 (15%) were of ILC histology. Seven of 14 patients with ILC had 18F-FDG PET/CT performed within 5 wk of the research 18F-FES PET/CT and no intervening change in management. For these 7 patients, the 18F-FES and 18F-FDG PET/CT studies were analyzed to determine the total number of tracer-avid lesions, organ systems of involvement, and SUVmax of each organ system for both tracers. Results: In the 7 comparable pairs of scans, there were a total of 254 18F-FES-avid lesions (SUVmax, 2.6-17.9) and 111 18F-FDG-avid lesions (SUVmax, 3.3-9.9) suggestive of malignancy. For 5 of 7 (71%) ILC patients, 18F-FES PET/CT detected more metastatic lesions than 18F-FDG PET/CT. In the same 5 of 7 patients, the SUVmax of 18F-FES-avid lesions was greater than the SUVmax of 18F-FDG-avid lesions. One patient had 18F-FES-avid metastases with no corresponding 18F-FDG-avid metastases. There were no patients with 18F-FDG-avid distant metastases without 18F-FES-avid distant metastases, although in one patient liver metastases were evident on 18F-FDG but not on 18F-FES PET. Conclusion:18F-FES PET/CT compared favorably with 18F-FDG PET/CT for detection of metastases in patients with metastatic ILC. Larger prospective trials of 18F-FES PET/CT in ILC should be considered to evaluate ER-targeted imaging for clinical value in patients with this histology of breast cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ulaner GA, Jhaveri K, Chandarlapaty S, et al. Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. J Nucl Med. 2020. PMID: 32680923. doi:10.2967/jnumed.120.247882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。